Company intelligence / Profile preview

OnCusp Therapeutics

Ownership: Private
Employees: ~16
Development stage: Phase 1

Overview

Early Phase I data from the ongoing multicenter study of CUSP06 show promising anti-tumor activity with manageable safety profile. The FDA granted Fast Track Designation to this program in February 2025 for platinum-resistant ovarian cancer[8][3][6].

Therapeutic areas: Oncology
Modalities: ADC primarily
Industry: Biotech

Drug pipeline

2 assets

cusp06

1 more asset in the full pipeline.

Request access →

Partnerships

Global partnership excluding China with Chinese biotech partner

Beyond the preview

Go deeper on OnCusp Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OnCusp Therapeutics.

Explore the full profile